Loading...
Loading...
- Cowen & Co initiated coverage on Molecular Partners MOLN with an Outperform rating and a Price Target of $50, implying an upside potential of more than 150%.
- The company and its partner Novartis AG NVS recently shared preclinical data showing that ensovibep retains full potency and viral inhibition against all known COVID-19 variants in circulation, including the key Delta variants.
- It outlined progress on its global Phase 2/3 study in ambulatory COVID-19 patients.
- Interim data from EMPATHY Phase 2/3 trial is expected in H2 2021, and complete topline data expected in early 2022.
- The company started trading in the U.S market just a month back, wherein it sold 3 million shares at $21.25 each.
- The stock is already trading on the Swiss exchange since 2014.
- Price Action: MOLN shares are up 3.3% at $19.88 during the premarket session on the last check Tuesday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in